Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HISERPIA vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
HISERPIA (risperidone) is an atypical antipsychotic that acts as a serotonin 5-HT2A and dopamine D2 receptor antagonist. It also binds to alpha1-adrenergic and histamine H1 receptors with high affinity, contributing to its therapeutic and side effect profile.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Schizophrenia in adults and adolescents aged 13-17 years,Bipolar I disorder acute manic or mixed episodes as monotherapy or adjunct to lithium/valproate in adults,Irritability associated with autistic disorder in children and adolescents aged 5-16 years,Off-label: Anxiety disorders, obsessive-compulsive disorder, post-traumatic stress disorder, Tourette syndrome, dementia-related psychosis (not FDA-approved)
Hypertension
Initial: 0.25 mg orally twice daily; increase gradually to usual maintenance dose of 0.5–2 mg/day in divided doses. Maximum: 3 mg/day.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Terminal elimination half-life is 12-15 hours; clinically, steady-state is reached after 2-3 days of regular dosing.
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Primarily metabolized by CYP2D6 and CYP3A4 to its major active metabolite, 9-hydroxyrisperidone (paliperidone). CYP2D6 poor metabolizers have higher risperidone levels. Minor pathways include N-dealkylation.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Primarily renal (60-70% as unchanged drug) and biliary/fecal (20-30% as metabolites).
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
Approximately 90% bound to albumin and alpha-1-acid glycoprotein.
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
1.5-2.5 L/kg; indicates extensive tissue distribution.
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral: 80-95% due to extensive absorption with limited first-pass metabolism.
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
No specific guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential for accumulation.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use.
Child-Pugh Class B or C: contraindicated; use not recommended.
Not recommended for children under 12 years; limited data available.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Start at 0.125 mg orally twice daily; increase slowly due to increased sensitivity and risk of hypotension.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
Increased risk of death in elderly patients with dementia-related psychosis. HISERPIA is not approved for this population.
None
Cerebrovascular adverse events (including stroke) in elderly dementia patients,Neuroleptic Malignant Syndrome (NMS),Tardive dyskinesia,Hyperglycemia and diabetes mellitus,Hyperprolactinemia,Orthostatic hypotension,Seizures,Leukopenia/neutropenia/agranulocytosis,Body temperature dysregulation,Dysphagia,Priapism
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Hypersensitivity to risperidone or any component of the formulation,Use in elderly patients with dementia-related psychosis (due to black box warning)
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Avoid alcohol and tyramine-rich foods (aged cheese, cured meats, fermented products) as they may exacerbate hypertensive effects. Grapefruit juice may alter drug metabolism; limit intake.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
First trimester: Case reports of major congenital malformations including neural tube defects and cardiovascular anomalies, likely due to inhibition of folate metabolism. Second and third trimesters: Associated with oligohydramnios, fetal renal dysfunction, and skull ossification defects. Risk category X.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Contraindicated in breastfeeding; excreted in human milk with M/P ratio >1 (2.5 based on limited data). Potential for severe adverse effects in the nursing infant, including kernicterus.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
Clearance increased by 30-50% during pregnancy; doses may need upward titration guided by therapeutic drug monitoring. Postpartum dose reduction recommended to avoid toxicity.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
Hisergia is a combination of reserpine (0.1 mg) and dihydroergocristine (0.5 mg) used for hypertension. Monitor for bradycardia and orthostatic hypotension, especially in elderly. Reserpine depletes catecholamines; avoid in patients with depression or peptic ulcer. Dihydroergocristine is an ergot alkaloid; caution with CYP3A4 inhibitors due to risk of ergotism. Titrate slowly and check blood pressure and heart rate regularly.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take exactly as prescribed; do not skip doses or double up.,Rise slowly from sitting or lying to prevent dizziness.,Avoid driving or operating heavy machinery until you know how this medicine affects you.,Report any signs of depression, slow heartbeat, or fainting to your doctor.,Do not drink alcohol; it may worsen side effects.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HISERPIA vs ALDORIL D30, answered by our medical review team.
HISERPIA is a Antihypertensive that works by HISERPIA (risperidone) is an atypical antipsychotic that acts as a serotonin 5-HT2A and dopamine D2 receptor antagonist. It also binds to alpha1-adrenergic and histamine H1 receptors with high affinity, contributing to its therapeutic and side effect profile.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HISERPIA and ALDORIL D30 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HISERPIA is: Initial: 0.25 mg orally twice daily; increase gradually to usual maintenance dose of 0.5–2 mg/day in divided doses. Maximum: 3 mg/day.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HISERPIA and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HISERPIA is classified as Category C. First trimester: Case reports of major congenital malformations including neural tube defects and cardiovascular anomalies, likely due to inhibition of folate metabolism. Second an. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.